Shkreli Planet

• AAPL appears expensive at about 34× earnings; avoid chasing it at this valuation, and reassess if the multiple falls into a more attractive range.
• Monitor iPhone demand, services growth, and whether higher R&D spending produces successful new products before considering a purchase.

The speaker’s highest-conviction view is bearish on Palantir (PLTR): at the valuation discussed, consider avoiding or reducing exposure unless revenue growth, margins, and customer demand show the company can defend its edge against Anthropic and OpenAI. No specific sell price or timeframe was provided, so reassess after upcoming results rather than relying on a price target.

• Humacyte (HUMA): Treat this as a high-risk, wait-for-proof story; monitor whether revenue grows beyond $400,000 and whether the increase from 34 to 49 hospitals leads to repeat use and sustained sales.
• OraSure Technologies (OSUR): The Ebola-testing opportunity is uncertain, so consider waiting for earnings evidence of demand before adding exposure or deciding whether to exit.
• The discussion provides no current investment thesis for Rocket Lab (RKLB) or Palantir (PLTR); past missed gains alone are not a reason to buy.

The comments offer no actionable trade or specific security: the bullish view on AI is too broad to identify an investment, and no ticker, valuation, or timeframe is provided. Treat public funds’ discounts to NAV as a reason to investigate underlying assets—not as a buy signal without fund-specific analysis. The mentions of SL Green (SLG), Liquid Trading, and Citadel provide no investment thesis or recommendation.

• Consider a bearish Amazon (AMZN) thesis: the speaker called it a short and estimated fair value at $140, citing slow retail growth, heavy capital spending, and roughly negative $30 billion in free cash flow.
• Before acting, monitor AWS growth, retail margins, capital expenditures, and free cash flow; the $140 estimate is assumption-dependent, not a guaranteed price target.
• Treat AI-cloud infrastructure spending as a risk to watch: a future capex hangover could pressure returns if demand fails to justify the investment.

• Avoid buying Alphabet (GOOGL/GOOG) for now; wait for more stable Search and advertising trends and clearer returns on its AI spending.
• Research Genmab (GMAB) further: the speaker called its result “incredible,” but gave no specific recommendation or valuation.
• The comments provide no actionable trade on Eli Lilly (LLY), Moderna (MRNA), or SanDisk.

• Avoid or underweight Intel (INTC) near term: weak Q4 revenue guidance of $15–16 billion and fab-execution concerns cloud the turnaround; the speaker’s possible $20 downside is speculative, not a formal target.
• Treat AMD (AMD) cautiously as PC inventory reductions could pressure its client business, but the discussion provides no AMD-specific valuation or price target.
• For semiconductor investments, prioritize companies showing clear revenue and margin gains from AI rather than assuming AI demand will lift the entire sector.

• Petrobras (PBR) and Brazilian stocks warrant caution: political and currency risks remain, and no attractive buy level was identified.
• Moderna (MRNA) and Merck (MRK) have a promising cancer-treatment opportunity, but assess clinical evidence, competition from Keytruda, and which company is likely to capture the value.
• Humacyte (HUMA) is a high-risk, divided-view story; watch for actual sales and patient use rather than relying on trial headlines, hospital counts, or overseas interest.
• Netlist (NLST) is a speculative, catalyst-driven idea: verify licensing-payment terms, memory-reselling economics, and sustainable earnings before considering an investment.
• Ultragenyx (RARE) was presented as a potential value opportunity, but the claim that it could double lacks a timeframe or valuation support; weigh pipeline prospects against research spending.

• Treat Anthropic as a high-growth but speculative private-market opportunity; reported revenue growth and positive cash flow are promising, but the transcript provides no reliable valuation or confirmed share price.
• Before investing, verify the offering price, preferred-share conversion terms, dilution, and off-balance-sheet compute arrangements; do not rely on the floated $1 trillion valuation or $100 billion founder-stake estimate.
• GS, Spark Capital, AIG, Bristol Myers, and DoorDash are mentioned without a stock thesis or actionable recommendation.

• Treat consumer longevity regimens and BPC claims cautiously; the discussion cites no convincing evidence or investment recommendation.
• For biotech research, prioritize companies with results from large, well-designed clinical trials over individual testimonials or biomarker experiments.
• Alzheimer’s, Parkinson’s, and cancer research may address significant unmet needs, but no specific companies, securities, or price targets were identified.

Pfizer (PFE) merits further research: the outlook on its pipeline was more positive than expected, but no price target or timeframe was given, so the comments alone don’t support a buy decision. Size any investment according to the strength and rarity of the opportunity, rather than confidence or the desire for a bigger gain.

• AMZN appears well-positioned in AI infrastructure after raising guidance, but monitor whether spending on Nvidia hardware and Trainium translates into durable revenue and cash flow.
• NVDA and GOOGL are key beneficiaries of data-center expansion, but avoid assuming AI-chip demand will grow indefinitely; look for evidence in customer orders and cash generation.
• Across AI infrastructure and neoclouds, favor companies with manageable debt and credible returns on investment, and be cautious of valuations that rely on optimistic growth or adjusted earnings that obscure costs.

• Consider a cautious or underweight stance on Moderna (MRNA) near the cited $234–$235 price: the speaker’s rough model suggested its cancer-vaccine opportunity would need about $25 billion in revenue to support that valuation, and the vaccine is not yet approved.
• Watch upcoming ESMO data and the treatment’s regulatory and commercial progress before reassessing MRNA; the bullish case depends on unusually large sales, with some economics shared with Merck (MRK).
• The speaker was bearish on CoreWeave (CRWV) and data-center stocks, citing debt and weak share performance, but provided no price targets or detailed analysis.

• The strongest actionable theme is a diversified basket of robotics companies for investors with a 10–20-year horizon; the eventual winners are uncertain, so avoid concentrating on one name.
• Revolution Medicines (RVMD) is presented as a potentially underappreciated cancer-treatment opportunity, but its substantial prior rise makes valuation and commercial execution important risks to assess before investing.
• Treat NVIDIA (NVDA), Google (GOOG/GOOGL), Uber (UBER), Shopify (SHOP), and the Cloudflare (NET)/FactSet (FDS) trade as historical examples—not current buy or short recommendations, since no current valuations or trade setups are provided.

• Treat Spruce Biosciences (SPRB) as a high-risk, milestone-driven speculation: monitor the anticipated BLA submission, FDA decision, and early sales rather than relying on the speaker’s unguaranteed “double or triple” upside estimate.
• No near-term trade is supported for Abivax (ABVX), Revolution Medicines (RVMD), Moderna (MRNA), Praxis Precision Medicines (PRAX), or SanDisk; the insights provide no actionable targets or catalysts for these names.
• For biotech investments, size positions cautiously and be prepared for volatility and a potentially three-to-five-year horizon.

The discussion provides no substantiated, actionable buy or sell recommendation for PFE, RVMD, or LQDA; it offers no price targets, timelines, or company-specific evidence. Treat claims that AI will soon cure cancer or dramatically shorten drug development with caution, since clinical trials remain essential and the proposed time savings were not verified.

• Spruce Biosciences (SPRB) is the clearest high-upside catalyst opportunity: the speaker expects a BLA filing that quarter and potential FDA approval within five to six months, but approval and commercial success are uncertain.
• Treat AST SpaceMobile (ASTS) cautiously: the speaker questioned whether its roughly $20 billion valuation is justified by less than $200 million in revenue and the sector’s capital-intensive, potentially low-margin economics.
• The speaker favored SanDisk (SNDK) and semiconductor exposure over biotech in a hypothetical comparison, citing AI enthusiasm, but gave no price target or detailed valuation case.

The only directional view is a potential short in SanDisk (SNDK) based on possible Chinese competition, but the discussion offers no evidence, price target, or timing—investigate the threat before acting. No other company or sector receives a sufficiently specific, supported trade recommendation.

• Consider NVIDIA (NVDA) as part of a broader semiconductor investment: AI-compute demand could grow, but model-efficiency gains and competition create meaningful uncertainty.
• Meta (META) is a constructive AI-product play, with distribution and product development cited as strengths; no valuation or price target was provided.
• Treat OpenAI and Anthropic as positive but inaccessible or speculative opportunities based on the discussion; no investment terms or valuations were given.
• Avoid making near-term investment decisions on AI drug discovery claims without evidence of successful, approved drugs; the speaker expects no AI-relevant drug within 10 years.

Avoid shorting quantum-computing stocks solely on skepticism: the technology may be overhyped, but short positions can incur large losses if timing is wrong. Treat photonic-computing startups such as Neurophos, OptiCore, and Lumai as speculative watchlist names; technical hurdles remain, and no investment targets or commercialization timelines are provided. The insights offer no clear buy or sell signal for NVIDIA (NVDA).